Plain-English translation of NCT06995573 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a medication called that is designed to help improve memory and thinking in people with mild to moderate Alzheimer's disease. The medication works by targeting specific brain receptors involved in memory and attention. Researchers want to understand how safe the medication is and whether it helps slow cognitive decline.
Current Alzheimer's treatments help some patients, but many people still experience progressive memory loss and cognitive decline. This medication represents a new approach to targeting the brain changes that occur in Alzheimer's disease, and researchers want to see if it can make a meaningful difference for patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to take either the new medication at a set dose, the new medication combined with another medication to manage side effects, or a placebo (inactive pill). You will take your assigned treatment daily by mouth. You will need to visit the research clinic for several appointments where researchers will test your memory and thinking, ask about any side effects, and monitor your overall health. Your caregiver will also be asked to provide observations about your cognitive and behavioral changes during the study.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Austria
Germany